source
- Merck halts development of BTK inhibitor nemtabrutinib after safety concernsMerck announced it is ending development of the oral BTK inhibitor nemtabrutinib (MK-1026), which it acquired in the $2.7 billion ArQule purchase. The decision follows a recommendation from an ext…
- Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchaseMerck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…